Address: Lochhamer Schlag 17, 82166 Gräfelfing,Germany
Tel: +49 (0)89 45 45 0-0
Web: www.ribosepharm.de or www.hikma.com
Hikma is a leading generic pharmaceutical company with a significant presence in the Middle East and North Africa (”MENA”) region, the United States and Europe. Currently, the group sells 369 pharmaceutical products in 767 dosage strengths and forms in 49 countries. 40 of our products are sold under promotion and distribution agreements with, or licenses from, 16 originator pharmaceutical companies and three generic pharmaceutical companies.Its listing on the London Stock Exchange in November 2005 marked the beginning of an exciting new phase in the Company’s development. The financial flexibility that Hikma gained through the listing leaves it in a good position to grow, both organically and through acquisitions.The group’s strategy for growth is to build a strong and diverse product portfolio; to expand its geographic reach; to develop and leverage global research and development capabilities and API sourcing strengths; and to continue to maintain the very high standards of manufacturing capabilities.The german company Ribosepharm, founded in 1983, was a mid-sized pharmaceutical company who boast 20 years of commitment to oncology with its products in cancer therapy. In January 2007 it became a member of the Hikma Group via acquisition.
One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation…
Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, launches a critique of current pharmaceutical…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
At the recent World Economic Forum in Davos, Chair of the Executive Board and CEO of Merck, Belén Garijo, speaking in a session on workforce transformation in the digital era,…
In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the…
The latest from German pharma, including Merck KGaA’s increased gamble on external innovation, Bayer’s focus supply chain stability, CatalYm’s EUR 50 million series C financing and Boehringer Ingelheim’s deal with…
A roundup of some of the biggest recent stories from German pharma, including the latest on beleaguered Bayer CEO Werner Baumann, Merck KGaA’s latest investments in France and Germany, and…
A snapshot of Germany, one of the European pharma hotspots featured in PharmaBoardroom’s latest report, InFigures: European Pharma Hotspots 2022. With the largest market value in Europe, Germany remains at…
The latest from German pharma, including Bayer’s 2021 financial results, the country’s plan to spend $3.14 billion on vaccine capacity to cover Covid-19 outbreaks until 2029, and Boehringer Ingleheim’s case…
See our Cookie Privacy Policy Here
